Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P01871

UPID:
IGHM_HUMAN

ALTERNATIVE NAMES:
Ig mu chain C region; Ig mu chain C region BOT; Ig mu chain C region GAL; Ig mu chain C region OU

ALTERNATIVE UPACC:
P01871; A0A075B6N9; A0A0G2JQL4; P04220; P20769

BACKGROUND:
Immunoglobulin heavy constant mu, known alternatively as Ig mu chain C region, is integral to B lymphocyte function and humoral immunity. It mediates the effector phase of immunity, crucial for antigen elimination. IgM antibodies, found in both membrane-bound and soluble forms, are essential for early defense mechanisms against external invaders and in the recognition of abnormal cells.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Immunoglobulin heavy constant mu could open doors to potential therapeutic strategies. Its involvement in Agammaglobulinemia 1, autosomal recessive, a primary immunodeficiency, presents a compelling case for exploring IgM-targeted therapies to enhance immune surveillance and combat infections.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.